IBXX.F Stock Overview
Provides medical imaging technologies using magnetic resonance.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Imagion Biosystems Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.035 |
| 52 Week High | AU$0.99 |
| 52 Week Low | AU$0.035 |
| Beta | 2.05 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -80.11% |
| 33 Year Change | -99.37% |
| 5 Year Change | n/a |
| Change since IPO | -98.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| IBXX.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | 0.9% | -0.8% |
| 1Y | -80.1% | 27.5% | 31.5% |
Return vs Industry: IBXX.F underperformed the US Medical Equipment industry which returned 29.7% over the past year.
Return vs Market: IBXX.F underperformed the US Market which returned 31.9% over the past year.
Price Volatility
| IBXX.F volatility | |
|---|---|
| IBXX.F Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: IBXX.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine IBXX.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | n/a | imagionbiosystems.com |
Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers, as well as in preclinical stage to treat prostate, ovarian, brain, and pancreatic cancer.
Imagion Biosystems Limited Fundamentals Summary
| IBXX.F fundamental statistics | |
|---|---|
| Market cap | US$794.50k |
| Earnings (TTM) | -US$4.27m |
| Revenue (TTM) | US$4.00m |
0.2x
P/S Ratio-0.2x
P/E RatioIs IBXX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IBXX.F income statement (TTM) | |
|---|---|
| Revenue | AU$5.92m |
| Cost of Revenue | AU$3.38m |
| Gross Profit | AU$2.54m |
| Other Expenses | AU$8.86m |
| Earnings | -AU$6.32m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.18 |
| Gross Margin | 42.95% |
| Net Profit Margin | -106.79% |
| Debt/Equity Ratio | -60.1% |
How did IBXX.F perform over the long term?
See historical performance and comparison